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Congenital Treatment) Registry in 2010. By 2013, its patient enrollment exceeded that of other current and historical
congenital catheterization registries.
OBJECTIVES This study sought to describe procedural results and safety of 6 common congenital interventions
performed in patients enrolled during the IMPACT Registry’s initial periods.
METHODS With speciﬁed exclusions, we compiled registry data from patients enrolled in the IMPACT Registry from
January 2011 through March 2013 who underwent 1 of the following isolated procedures: device closure of atrial septal
defect (ASD); device closure of patent ductus arteriosus (PDA); pulmonary valvuloplasty; aortic valvuloplasty; coarctation
of the aorta angioplasty and stenting; and pulmonary artery stenting. Patient data, procedural data and results, and
adverse events (AEs) were reviewed and described.
RESULTS In 4,152 catheterizations, 1 isolated procedure was reported. There were 1,286 single-ASD procedures,
1,375 PDA procedures, 270 “typical” pulmonary valve procedures, 305 aortic valve procedures, 671 aortic procedures, and
245 pulmonary artery procedures. The reported procedure was performed in >95% of catheterizations. Stated outcomes
were accomplished in >98% of ASD and PDA procedures, but less commonly in the others, with coarctation angioplasty
procedures being the least successful (51%). Reported major AE rates ranged from 0% to 3.3%; total AE rates ranged
from 5.3% to 24.3%.
CONCLUSIONS Contemporary community practice, procedural outcomes, and safety for 6 common congenital inter-
ventional procedures are reported. These benchmarks may be compared with individual center results and historical single-
center and multicenter results. (J Am Coll Cardiol 2014;64:2439–51) © 2014 by the American College of Cardiology
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go, California; yDivision of Cardiology, Department of Pediatrics, Children’s Healthcare of Atlanta, Emory University, Atlanta,
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cinnati, Ohio; xDivision of Cardiology, Department of Pediatrics, Toronto Hospital for Sick Children, University of Toronto,
ronto, Ontario, Canada; kDepartment of Cardiology, Boston Children’s Hospital, Harvard University, Boston, Massachusetts;
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2440M ost previous reports of interven-tional procedures in congenitalheart disease have been single-
center or single-device studies. Although
there have been some registry-based studies,
historically, congenital catheterization regis-
tries have been physician initiated and
limited. The Michigan and the European PDA
Coil Registries (1,2) and the VACA (Valvulo-
plasty and Angioplasty of Congenital Anoma-
lies) Registry (3) closed decades ago and
reported on procedures using somewhat
dated technologies. The MAGIC (Mid-Atlantic
Group of Interventional Cardiology) Registry
(3) and the Congenital Cardiovascular Inter-
ventional Study Consortium (CCISC) (4) are
active, but have limited scopes. The C3PO
(Congenital Cardiac Catheterization Project
on Outcomes) Registry (5), which generated
several groundbreaking studies, involves a
relatively limited number of study centers.
The IMPACT (Improving Pediatric and Adult
Congenital Treatment) Registry, 1 registry in the Na-
tional Cardiovascular Data Registry (NCDR), was
launched in 2010 (6). As of October 2013, the IMPACT
Registry had 81 participating centers and enrolled
>26,000 catheterization episodes of care. Because of
wide congenital heart center participation, the IMPACT
Registry has the potential to deﬁne community practice
and contemporary practice benchmarks. Moreover, its
sophistication, size, and scope give IMPACTRegistry the
potential to support better powered, more nuanced re-
views and analyses than previous studies.SEE PAGE 2452In this report, we describe the procedural results
and safety of 6 common congenital interventions
performed in patients enrolled in the IMPACT Regis-
try during its initial periods. These procedures are
device closure of an atrial septal defect (ASD), device
closure of patent ductus arteriosus (PDA), pulmonary
valvuloplasty (PV), aortic valvuloplasty (AV), coarc-
tation of the aorta (Coarct) angioplasty and stenting,
and pulmonary artery (PA) stenting.ildren’s Center, Johns Hopkins University, Baltimore, Maryland;
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NATIONAL CARDIOVASCULAR DATA REGISTRY. The
IMPACT Registry is an initiative of the American College
of Cardiology Foundation and was previously described
(7). The Registry collects data for use in development of
performance and quality metrics, quality improvement
programs, and peer-reviewed outcomes research
focused on patients with congenital heart disease un-
dergoing cardiac catheterizations. Demographic, clin-
ical, procedural, and institutional data elements are
collected at participating centers, entered via a Web-
based platform, and collected in a secure, centralized
database. A description of IMPACT Registry data ele-
ments and deﬁnitions is available online (8). When not
pre-speciﬁed, deﬁnition of other aspects of data ele-
ments was left to the discretion of participating centers.
The IMPACT Registry has a data quality program
consistent with that described for the NCDR (9). The
program ensures data completeness, consistency, and
accuracy. In this study, all reported data met Registry
criteria for completeness and consistency. During data
collection for this study, IMPACT Registry auditing
procedures were under development. Therefore, data
accuracy was not veriﬁed by audits. Patient consent
forms of centers enrolled in the IMPACT Registry
include the provision that parties agree to allow use of
clinical data in deidentiﬁed quality review. Because
patient information is collected anonymously and
without unique patient identiﬁers, the IMPACT Reg-
istry research studies meet the deﬁnition of research
not requiring speciﬁc informed consent.
THIS STUDY. This study focuses on describing
IMPACT Registry data pertaining to procedural ele-
ments and results in patients who underwent 1 of the
following procedures: device closure of ASD, device
closure of PDA, PV, AV, Coarct angioplasty and
stenting, and PA stenting. Data from January 2011 to
March 2013 were collected from a total of 4,152 cath-
eterization laboratory visits that included 1 of the
aforementioned procedures.
Only patients who had “isolated” procedures were
eligible for inclusion; patients undergoing more thanzzChildren’s Hospital of Philadelphia, University of
alth System, George Washington University, Wash-
diology Foundation’s National Cardiovascular Data
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proctor for St. Jude Medical. All other authors have
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24411 of the 6 common interventional procedures or un-
dergoing 1 of the common procedures and another
interventional procedure were excluded. Further
exclusion criteria included the following: 1) ASD
procedures having multiple devices implanted; 2)
pulmonary valve procedures, with highly dysplastic
valves, supravalve stenosis, or signiﬁcant infundib-
ular stenosis; and 3) aortic valve procedures using
dual-balloon catheters.
Data regarding patient characteristics, procedural
indications (including hemodynamic data), proce-
dural elements and results, and adverse events (AEs)
are included in this report. An AE was deﬁned as
occurrence of any of the following: cardiac arrest; air
embolus; arrhythmia; arrhythmia requiring cardio-
version, antiarrhythmic medication; permanent or
temporary pacemaker; new heart valve regurgitation;
tamponade; embolic stroke; new requirement for
dialysis; airway event requiring intubation; event
requiring extracorporeal membrane oxygenation or
left ventricular assist device; bleeding event;
bleeding event at access site; hematoma at access
site; retroperitoneal, gastrointestinal, or genitouri-
nary bleeding; red blood cell/whole blood trans-
fusion; device malposition; device thrombus; device
embolization; unplanned surgery; or subsequent
cardiac catheterization due to a catheterization-TABLE 1 ASD Procedures
Total
Age <30 Days
(Neonates)
No. of procedures* 1,286 2
Indication
RV volume overload 1,038 (81.0) 1
Stroke prevention 165 (13.0) 0
Qp/Qs 1.8  0.8
1.7 (1.3–2.1)
2.9  1.5
2.9 (1.8–3.9)
ASD size, mm 13.1  6.3 13.0  7.1
Device implanted 1,228 (95.7) 2 (100.0)
Amplatzer 852 (69.3) 2
HELEX 352 (28.6)
Other 23 (1.9)
Not speciﬁed 1
Residual >3 mm 22 (1.8) 0
Death
Procedural 0
Episode of care 2 0
AE (any) 1,280
73 (5.7) 1 (50.0)
MAE 15 (1.2) 0
Tamponade (erosion) 3 0
Embolization 22 (1.7) 0
Unplanned cardiac surgery 10 (0.8) 0
Values are n, n (%), mean  SD, or median (interquartile range). *Number of procedure
AE ¼ adverse event; ASD ¼ atrial septal defect; MAE ¼ major adverse event; Qp/Qs ¼related complication. Major adverse events (MAEs)
were deﬁned as need for permanent or temporary
pacemaker, cardiac arrest, cardiac tamponade (re-
quiring pericardial drainage), embolic stroke (within
72 h), and unplanned cardiac surgery (due to cathe-
terization complication). Reported AEs occurred dur-
ing the catheterization or the hospitalization during
which the procedure was performed (episode of care)
and were attributable to the catheterization proce-
dure. Deaths occurring during the episodes of care are
reported; however, registry data do not specify
whether death was attributed to the catheterization
procedure. Reported deaths may be complications of
catheterization or attributable to other procedures
occurring during the episodes of care (e.g., cardiac
surgery) or unrelated patient comorbidities.
STATISTICAL ANALYSIS. Descriptive statistics for all
patients undergoing 1 of the 6 major interventional
procedures are presented. Continuously distributed
variables are reported as mean  SD and categorical
variables are reported as frequencies.
RESULTS
DEVICE CLOSURE OF A SINGLE ASD. Device occlu-
sion or attempt to occlude a single isolated ASD was
reported in 1,286 patients. (Table 1). Only 19 patientsAge 30 Days to 1 Year
(Infants)
Age 1–18 Years
(Children)
Age >18 Years
(Adults)
17 939 328
8 (47.0) 861 (92) 168 (51.5)
1 (6.0) 35 (3.8) 129 (39.6)
2.2  1.0
1.9 (1.6–2.2)
1.8  0.7
1.7 (1.3–2.1)
1.8  1.2
1.5 (1.1–2.0)
8.3  2.7 13.0  5.5 13.5  8.2
15 (88.2) 897 (95.7) 314 (96.0)
13 639 198
2 239 111
0 18 (2.0) 4 (1.3)
1 (respiratory) 0 1 (cardiac)
2 (11.8)
937
53 (5.7)
326
17 (5.2)
1 (5.9) 8 (0.9) 6 (1.8)
0 1 2
0 17 (1.8) 5 (1.5)
0 7 (0.7) 3 (0.9)
s reporting this individual data element.
pulmonary ﬂow/systemic ﬂow; RV ¼ right ventricular.
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2442were neonates (<30 days old) or infants (30 days to
1 year old). There were 939 children (73%) (between
1 and 18 years of age), and 328 adults (26%) (older
than 18 years of age).
The primary reported indication for ASD closure
was right ventricular volume overload in 1,038 pa-
tients (81.2%), followed by stroke prevention in 165
patients (12.9%). Additional primary indications in
small numbers (from 0.4% to 1.8%) included chronic
lung disease, failure to thrive, recurrent respiratory
infections, cyanosis, and migraines. When reported,
hemodynamic measurements at catheterization yiel-
ded a mean pulmonary ﬂow/systemic ﬂow (Qp/Qs)
ratio of 1.8  0.8 and median of 1.7 (interquartile
range: 1.3 to 2.1). These data were not reported in 133
adult patients (41%) and in 98 children (10%). Mean
ASD size was 13.1  6.3 mm, and ASD sizes were
similar in children and adults, but was smaller (8.3
mm) in infants.
Balloon sizing was performed in 82.3% of pa-
tients, more commonly in those older than 1 year.TABLE 2 PDA Procedures
Total
Age <30 Days
(Neonates)
No. of procedures* 1,375 10
Indication
LV volume overload 751 (54.8) 6
SBE prevention 517 (37.7) 2
Pulmonary HTN 102 (7.4) 2
Qp/Qs 1.7  1.3
1.3 (1.1–1.8)
3.4  3.1
1.9 (1.8–4.0)
PDA type 1,333 9
A (conical) 829 (62.2) 8
B (window) 20 (1.5)
C (tubular) 257 (19.3)
D (complex) 66 (5.0)
E (elongated) 161 (12.1) 1
PDA-treated 1,357 (98.8) 9 (90)
Coil 216 (15.9)
Device 501 (36.9)
Not reported 640 (47.1)
Residual >3 mm 14 (1.0) 1
Death
Procedural 0
Episode of care 6 1 (resp)
AE (any) 1,366
72 (5.3) 4 (40.0)
MAE 1,370
3 (0.2)
1
Embolization 1,371
16 (1.2)
0
Unplanned cardiac surgery 1,370
2 (0.1) 1 (10.0)
Values are n, n (%), mean  SD, or median (interquartile range). *Number of procedure
HTN ¼ hypertension; LV ¼ left ventricular; PDA ¼ patent ductus arteriosus; resp ¼ pAmong patients having balloon sizing, the stop-ﬂow
technique, when speciﬁed, was performed in 89.0%
of cases. Only 56% of cases reported ASD rim mea-
surement. Rim measurement was less common in
adults (36.9%) than in children (62.4%).
An ASD device was implanted in 95.7% of cathe-
terizations (1,228 of 1,283). Amplatzer septal occlud-
ers (ASOs) were implanted in 852 patients (69.3%),
whereas HELEX occluders (W. L. Gore & Associates,
Flagstaff, Arizona) were implanted in 352 patients
(28.6%). Insufﬁcient ASD rim was given as the reason
for failure to implant devices in 48.1% of patients (26
of 54). Signiﬁcant residual shunts ($3 mm) immedi-
ately after device placement were noted in 1.8% of
patients (22 of 1,226).
The mean length of hospital stay (LOS) from
admission to discharge was 1.6  7.9 days; median
was 1.0 days. There were no deaths in the catheteri-
zation laboratory. However, 2 patients died during
the episode of care: 1 adult from a cardiac cause and
an infant from a pulmonary cause. AEs were reportedAge 30 Days to 1 Year
(Infants)
Age 1–18 Years
(Children)
Age >18 Years
(Adults)
359 962 44
241 (67.5) 488 (50.9) 16 (36.4)
48 (13.4) 443 (46.2) 24 (54.5)
68 (19.0) 28 (2.9) 4 (9.1)
2.3  2.1
1.9 (1.4–2.7)
1.4  0.6
1.2 (1.0–1.5)
1.5  0.8
1.4 (1.1–1.6)
346 936 42
187 (54.0) 608 (65.0) 26 (61.9)
2 (0.6) 17 (1.8) 1 (2.4)
97 (28.0) 152 (16.2) 8 (19.0)
16 (4.6) 47 (5.0) 3 (7.1)
44 (12.7) 112 (12.0) 4 (9.5)
348 (97.2) 956 (99.5) 44 (100.0)
3 10 0
5 (4 resp) 0 0
358
29 (8.1)
954
39 (4.1)
0
1 1 0
3 (0.8)
958
13 (1.4)
0
1 (0.3)
0 0
s reporting this individual data element.
ulmonary cause; SBE ¼ subacute endocarditis; other abbreviations as in Table 1.
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2443in 5.7% of patients (73 of 1,281). MAEs were noted in
1.2% of patients (15 of 1,281). Cardiac tamponade (due
to device erosion) occurred in 0.2% of patients (3 of
1,285). Device embolization occurred in 1.7% (22 of
1,285). Catheter retrieval was performed in 72.7% (16
of 22). Unplanned cardiac surgery was performed in
10 patients, including those with tamponade or
device embolization.
DEVICE CLOSURE OF PDA. Device occlusion or
attempt to occlude PDA was reported in 1,375 patients
(Table 2). There were only 10 neonates. Most patients
were infants (26.1%) or children (69.9%).
The primary reported indication for PDA closure
was left ventricular volume overload in 751 patients
(55%), followed by subacute endocarditis prevention
in 517 patients (37.7%) and pulmonary hypertension
in 102 (7.4%). In spite of controversy with respect to
use of standard oximetry for Qp calculation in PDA,
for consistency with prior datasets, measurements at
catheterization were reported with mean Qp/Qs ratio
of 1.7  1.3 and median ratio of 1.3 (IQR: 1.1 to 1.8).
These data were not reported in 204 children (21%),
49 infants (14%), and 12 adults (27%).
PDA were classiﬁed as Type A (conical) in 62% (829
of 1,333), Type B (window) in 1.5% (20 of 1,333), Type CTABLE 3 Pulmonary Valvuloplasty Procedures
Total
Age <30 D
(Neonate
No. of procedures* 270 78
Indication
Resting gradient 223 (82.6) 52 (66.7
Right-to-left shunting 16 (5.9) 15 (19.2
RV dysfunction 14 (5.2) 7 (9.0
Symptoms 17 (6.3) 4 (5.1)
Pre-procedural PV gradient, mm 47.0  19.7
45.0 (33.0–60.0)
75
52.9  2
54.0 (40.0–
PS treated 268 (99.3) 78 (100
Balloon technique 268
Single 249 (92.9) 75 (96.2
Double 17 (6.3) 2 (2.6)
Both 2 (0.7) 1 (1.3)
Post–single-balloon systolic gradient,
mm Hg
249
16.1  11.6
14.0 (9.0–20.0)
75
13.0  11
10.0 (6.0–1
<20 181 (73.0) 64 (85.3
Post–single-balloon pulmonary
insufﬁciency $2þ
224
14 (6.2)
69
7 (10.1
AE (any) 267
19 (7.1)
77
11 (14.3
MAE 0 0
Unplanned cardiac surgery 0 0
Values are n (%), n, mean  SD, or median (interquartile range). *Number of procedure
PS ¼ pulmonary stenosis; PV ¼ pulmonary valvuloplasty; other abbreviations as in Ta(tubular) in 19.3% (257 of 1,333), Type D (complex) in
5.0% (66 of 1,333), and Type E (elongated) in 12.1%
(161 of 1,333). Type A was the most common in all age
groups.
A coil or a device was implanted in 98.8% of
catheterizations (1,357 of 1,373). Devices were used in
70.0% and coils were used in 30.0%. In all age cate-
gories, device implant was more common than coils.
Signiﬁcant residual shunts ($3 mm), PA obstruction,
and aortic obstruction immediately after device and/
or coil implant were each noted in about 1.0%.
Mean patient length of hospital stay was 4.3 
21.8 days, and the median was <1 day. There were
no deaths in the catheterization laboratory. How-
ever, 6 patients died during the episode of care:
none attributed to a cardiac cause, and 5 attributed
to a pulmonary cause. AEs were reported in 5.3%
of patients (72 of 1,366), whereas MAEs occurred
in 0.2% (3 of 1,370). Device embolization occurred
in 1.2% of patients (16 of 1,371). Catheter retrieval
was performed in 69% of patients (11 of 16). Un-
planned cardiac surgery was performed in only 2
patients.
PULMONARY VALVULOPLASTY. Balloon PV in
patients with isolated “typical” valve morphologyays
s)
Age 30 Days to 1 Year
(Infants)
Age 1–18 Years
(Children)
Age >18 Years
(Adults)
93 83 16
) 86 (92.5) 75 (90.4) 10 (62.5)
) 1 (1.1) 0 0
) 4 (4.3) 2 (2.4) 1 (6.3)
2 (2.2) 6 (7.2) 5 (31.3)
4.1
70.0)
49.8  17.2
50.0 (37.0–61.0)
39.4  15.3
38 (30.0–46.0)
42.2  19.2
40 (36.5–41.0)
) 93 (100) 82 (98.8) 15 (93.8)
82 15
) 92 (98.9) 70 (85.4) 12 (80.0)
1 (1.1) 11 (13.4) 3 (20.0)
0 1 (1.2) 0
.8
6.0)
92
17.8  11.4
15.0 (10.0–20.0)
70
16.7  10.9
15.0 (10.0–21.0)
12
19.0  13.5
14.5 (10.0–21.0)
) 65 (70.7) 44 (63.8) 8 (66.7)
)
85
3 (3.5)
59
3 (5.1)
1
1 (9.1)
)
92
6 (6.5)
82
2 (2.4)
0
0 0 0
0 0 0
s reporting this individual data element.
ble 1.
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2444was reported in 270 patients. (Table 3): 78 neonates
(29%), 93 infants (34%), 83 children (31%), and
16 adults (5.9%).
The primary reported indication for valvuloplasty
was resting gradient (83% of patients). Right-to-left
shunting, a common criterion for critical pulmonary
stenosis, was cited in 15 neonates (19%). Right ven-
tricular dysfunction or symptoms were noted in a
small number of older patients.
The mean pre-procedure pulmonary valve systolic
gradient was 47.0  19.7 mm Hg, and the median was
45.0 mm Hg across all age groups. The mean and
median gradients among neonates (53 mm Hg
and 54 mm Hg, respectively) and infants (50 mm Hg
and 50 mm Hg, respectively) were higher than those
observed among children (39 mm Hg and 38 mm Hg,
respectively) and adults (42 mm Hg and 40 mm Hg,
respectively).
Balloon dilation of the pulmonary valve was per-
formed in 268 patients or in 99.3% of patients re-
ported for PV. The single-balloon technique was used
in the majority (93%) of patients in all age groups.
Among patients having single-balloon valvuloplasty,
the mean post-procedure systolic gradient rangedTABLE 4 Aortic Valvuloplasty Procedures (Single-Balloon Technique
Total
Age <30
(Neonat
No. of procedures* 305 101
Indication
Resting gradient 252 (82.6) 75 (74.3
LV dysfunction 35 (11.5) 21 (20.
Symptoms 18 (5.9) 5 (5.0
AV gradient, mm Hg 302
62.6  23.3
60.0 (48.0–75.0)
99
68.1  2
70.0 (55.0–
AS treated 305 (100.0) 101 (100
Post–single-balloon systolic gradient,
mm Hg
299
26.1  15.0
25.0 (15.0–35.0)
97
24.5  1
24.0 (15.0–
<30 184 (61.5) 63 (64.
Post–single-balloon aortic insufﬁciency
<2þ 252 (82.6) 83 (82.
2þ 46 (15.1) 16 (15.8
>2þ 7 (2.3) 2 (2.0
Death
Catheterization lab 0 0
Episode 6 5 (4 card
AE (any) 301
73 (24.3) 29 (29.
MAE 302
10 (3.3)
100
3 (3.0
Unplanned cardiac surgery 304
3 (1.0) 1 (1.0
Values are n (%), n, mean  SD, or median (interquartile range). *Number of procedure
AS ¼ aortic stenosis; AV ¼ aortic valvuloplasty; other abbreviations as in Table 1.from 13.0 mm Hg in infants to 19.0 mm Hg in adults
(mean of 16.1  11.6 mm Hg across all groups). A post-
procedure gradient <20 mm Hg was attained in 73%
of patients.
Pulmonary insufﬁciency $2þ was observed
in #10% of the single-balloon patients in all groups
after valvuloplasty. AEs were recorded in 19 episodes
of care (7.1%), most commonly among infants 11
(14.3%). There were no MAEs or unplanned surgeries.
AORTIC VALVULOPLASTY. Single-balloon AV was
reported in 305 patients (Table 4): 101 neonates
(33%), 76 infants (25%), 106 children (34.8%), and
22 adults (7.2%).
In most patients (252 or 83%), the primary indi-
cation for valvuloplasty was resting gradient. Left
ventricular dysfunction, a common criterion for
critical aortic stenosis, was cited in 21 neonates
(21%) and in 8 infants (10.5%). Symptoms were cited
in 5 additional neonates (5.0%), expanding the
critical group to 26% of enrolled neonates. Symp-
toms were also cited in 6 (27.3%) of the adults
enrolled.
The pre-procedure mean aortic valve systolic
gradient was 62.6  23.3 mm Hg, and the median was)
Days
es)
Age 30 Days to 1 Year
(Infants)
Age 1–18 Years
(Children)
Age >18 Years
(Adults)
76 106 22
) 67 (88.2) 94 (88.7) 16 (72.7)
8) 8 (10.5) 6 (5.7) 0
) 1 (1.3) 6 (5.7) 6 (27.3)
2.3
80.0)
75
59.7  19.5
60.0 (45.0–73.0)
59.1  19.6
59 (46.0–70.0)
64.2  44.4
51.5 (36.0–70.0)
.0) 76 (100.0) 106 (100.0) 22 (100.0)
3.0
33.0)
75
26.0  15.9
20.0 (15.0–35.0)
105
27.4  14.3
25.0 (15.0–35.0)
27.8  22.5
23.0 (9.0–36.0)
9) 48 (64.0) 60 (57.1) 13 (59.1)
2) 63 (82.9) 87 (82.1) 19 (86.4)
) 11 (14.5) 16 (15.1) 3 (13.6)
) 2 (2.6) 3 (2.8) 0
0 0 0
iac) 0 1 (not cardiac) 0
0) 25 (33.3)
104
14 (13.5)
5 (22.7)
)
75
2 (2.7)
105
5 (4.8)
0
) 1 (1.3)
105
1 (1.0)
0
s reporting this individual data element.
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244560.0 mm Hg across all age groups. Systolic gradients
ranged from 59.1  19.6 mm Hg among children to
68.1  22.3 mm Hg among neonates. The median
gradients ranged from 51.5 mm Hg in adults to 70.0
mm Hg in neonates.
Single-balloon dilation of the aortic valve was
performed in 305 patients or 100% of those reported
for this procedure. The mean post-procedure systolic
gradient was 26.1  15.0 mm Hg and was similar
across all groups. The median gradients ranged from
20.0 mm Hg in infants to 25.0 mm Hg in children.
However, only 61.5% of patients attained a post-
procedure gradient <30 mm Hg.
Aortic insufﬁciency of 2þ was observed in 46
patients (15.1%). Aortic insufﬁciency >2þ was seen in
7 patients (2.3%).
AEs were recorded in 73 patients (24.3%). MAEs
were reported in 10 patients (3.3%), and unplannedTABLE 5 Coarctation Angioplasty and Stenting Procedures
Total
Age <30
(Neonat
No. of procedures* 671 12
Indication 670
Resting gradient 351 (52.4) 6 (50.0
Hypertension 143 (21.4) 1 (8.3)
Angio appearance 108 (16.1) 2 (16.7
Ventricular dysfunction/failure 68 (10.2) 3 (25.0
Pre-procedure systolic gradient, mm Hg 669
28.6  17.4
25.0 (16.0–39.0)
24.3  1
20.0 (13.0
Coarctation treated 670
663 (99.0) 12 (100
Technique 663
Balloon 335 (50.5) 6 (50.0
Stent 251 (37.9) 5 (41.7
Both 77 (11.6) 1 (8.3)
Post–balloon systolic gradient, mm Hg 334
11.3  10.4
9.0 (4.0–16.0)
5
6.2  5
5.0 (3.0–
<10 170 (50.9) 4 (80.
>20 64 (19.2) 0
Post–stent systolic gradient, mm Hg 251
5.4  10.9
2.0 (0.1–6.0)
5
4.8  7
2.0 (0.1–
<10 210 (83.7) 4 (80.
>20 15 (6.0) 0
Death
Procedural 1 0
Episode of care 12 (7 cardiac) 2
AE (any) 663
115 (17.3)
17
6 (35.
MAE 667
8 (1.2) 3 (17.6
Unplanned cardiac or vascular surgery 668
5 (0.7)
0
Values are n, n (%), mean  SD, or median (interquartile range). *Number of procedure
Angio ¼ angiography; other abbreviations as in Table 1.cardiac surgery was reported in 3 patients (1.0%).
There were no catheterization laboratory deaths.
However, there were 6 deaths, 4 attributed to cardiac
causes during the episodes of care.
ANGIOPLASTY AND STENTING OF THE COARCT.
Balloon dilation and/or stenting of the Coarct were
reported in 671 patients (Table 5): 267 infants (39.8%),
300 children (44.7%), and 92 adults (13.7%), but only
12 neonates (1.8%).
The primary indication was reported to be resting
gradient in 351 patients (52.4%), hypertension in
143 patients (21.4%), angiographic appearance in 108
patients (16.1%), and ventricular dysfunction or fail-
ure in 68 patients (10.2%). The mean systolic gradient
ranged from 24.3 mm Hg in neonates to 33.1 mm Hg in
infants. Children and adults had similar mean gradi-
ents (25.7 mm Hg and 25.8 mm Hg, respectively).Days
es)
Age 30 Days to 1 Year
(Infants)
Age 1–18 Years
(Children)
Age >18 Years
(Adults)
267 300 92
266
) 166 (62.4) 158 (52.7) 21 (22.8)
17 (6.4) 70 (23.4) 55 (59.8)
) 40 (15.0) 56 (18.7) 10 (10.9)
) 43 (16.2) 16 (5.3) 6 (6.5)
8.6
–33.5)
265
33.1  19.6
30.0 (18.0–45.0)
25.7  13.6
24.0 (16.0–33.0)
25.8  19.0
20.0 (15.0–31.5)
.0)
266
266 (100.0) 294 (98.0) 91 (98.9)
266 294 91
) 252 (94.7) 75 (25.5) 2 (2.2)
) 8 (3.0) 171 (58.2) 67 (73.6)
6 (2.3) 48 (16.3) 22 (24.2)
.8
6.0)
252
11.1  10.6
8.0 (3.0–16.0)
75
12.5  10.3
10.0 (5.0–18.0)
2
4.5  0.7
4.5 (4.0–5.0)
0) 131 (52.0) 33 (44.0) 2 (100.0)
47 (18.7) 17 (22.7)
.1
5.0)
8
3.7  4.2
3.0 (0.6–4.5)
171
4.7  6.5
2.0 (0.1–6.0)
67
7.5  18.3
2.0 (0.1–7.0)
0) 7 (87.5) 143 (83.6) 56 (83.6)
0 9 (5.3) 6 (9.0)
0 1 (vascular) 0
8 (6 cardiac) 1 (vascular) 1 (cardiac)
3)
258
65 (25.2)
296
36 (12.2)
8 (8.7)
)
258
1 (0.4) 3 (1.0) 1 (1.1)
265
2 (0.8)
299
2 (0.7) 1 (1.1)
s reporting this individual data element.
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2446Angioplasty and/or stent implantation were per-
formed in 663 patients or 99.0% of patients reported
for angioplasty or stent implantation. Angioplasty
alone was performed in 335 patients (50.5%)
including 252 infants (94.7% of the infants). Stent
implantation was more commonly performed in
children (n ¼ 171, 58.2%) and adults (n ¼ 67, 73.6%).
The mean post-angioplasty systolic gradient was 11.3
 10.4 mm Hg, whereas the mean systolic gradient
post-stent implantation was 5.4  10.9 mm Hg. The
median systolic gradients were 9.0 mm Hg in angio-
plasty patients and 2.0 mm Hg in stent patients.
AEs were recorded in 115 patients (17.3%), MAEs
were reported in 8 patients (1.2%), and unplanned
surgeries were reported in 5 patients (0.7%).
One catheterization laboratory death attributed to a
vascular cause occurred in a child, and there were
12 deaths during episodes of care, 7 attributed to
cardiac causes.
PA STENOSIS STENTING. Stent implantation to
address proximal PA stenosis stenting was reported in
245 patients with biventricular physiology (Table 6).
Only 2 were neonates (0.8%), and there were 39TABLE 6 Pulmonary Artery Stenting Procedures
Total
Age <30 D
(Neonate
No. of procedures* 245 2
Indication
Resting gradient 96 (39.2) 2 (100.0
PA ﬂow discrepancy 55 (22.4) 0
Angio appearance 44 (18.0) 0
RV dysfunction/HTN 39 (15.9) 0
Pulmonary insufﬁciency 11 (4.5) 0
RVSP/LVSP 151
0.6  0.2
0.6 (0.5–0.7)
1
0.8 (0.8–
No. of stenoses/procedure
1 203 1
2 42 1
PA stenoses treated 287
285 (99.3)
3
3 (100.0
Post-/pre-procedure minimal vessel
diameter, mm
214
2.1  0.9
2.0 (1.6–2.5)
2.8  2.
2.0 (1.0–5
PA side-branch jailing 286
30 (10.5)
1 (33.3)
Death
Episode of care 3 (2 cardiac) 0
AE (any) 244
32 (13.2)
3
1 (33.3)
MAE 3 (1.2) 0
Unplanned cardiac or vascular surgery 1 (0.4) 0
Values are n (%), n, mean  SD, or median (interquartile range). *Number of procedure
LVSP ¼ left ventricular systolic pressure; PA ¼ pulmonary artery; RVSP ¼ right ventriinfants (15.9%), 175 children (71.4%), and 29 adults
(11.8%).
The primary indication was reported to be resting
gradient in 96 patients (39.2%), PA ﬂow discrepancy
in 55 patients (22.4%), angiographic appearance in
44 patients (18.0%), right ventricular dysfunction in
39 patients (15.9%), and pulmonary valve insufﬁ-
ciency in 11 patients (4.5%).
Two stenoses (both right and left PA) were
present in 42 patients, and 1 stenosis was present
in 203 patients. Of 287 total stenoses reported for
stent implantation, 285 implantations were success-
ful (99.3%).
The mean ratio of post-stent minimal vessel dia-
meter to pre-stent minimal vessel diameter was 2.1 
0.9. This ratio was higher among the younger age
groups (1.6 in adults and 2.5 in infants). Side-branch
jailing was reported in 30 patients (10.5%).
AEs were recorded in 32 patients (13.2%). There
were MAEs in 3 (1.2%), and unplanned surgery in
1 patient (0.4%). There were no catheterization
laboratory deaths and 3 deaths during the episodes of
care, 2 attributed to cardiac causes and none to a
vascular cause.ays
s)
Age 30 Days to 1 Year
(Infants)
Age 1–18 Years
(Children)
Age >18 Years
(Adults)
39 175 29
) 14 (35.9) 68 (38.9) 12 (41.4)
10 (25.6) 38 (21.7) 7 (24.1)
4 (10.3) 37 (21.1) 3 (10.3)
10 (25.6) 25 (14.3) 4 (13.8)
1 (2.6) 7 (4.0) 3 (10.3)
0.8)
20
0.7  0.2
0.7 (0.5–0.8)
114
0.6  0.2
0.6 (0.5–0.8)
16
0.5  0.2
0.5 (0.4–0.6)
28 149 25
11 26 4
)
50
50 (100.0)
201
201 (100.0)
33
31 (93.9)
3
.3)
33
2.5  0.8
2.6 (2.0–3.0)
153
2.1  0.9
2.0 (1.5–2.5)
25
1.6  0.6
1.6 (1.3–2.1)
49
2 (4.1)
24 (11.9) 3 (9.1)
2 (1 cardiac) 1 (cardiac) 0
38
10 (26.3)
174
16 (9.2) 5 (17.2)
1 (2.6) 1 (0.6) 1 (3.4)
0 1 (0.6) 0
s reporting this individual data element.
cular systolic pressure; other abbreviations as in Tables 1, 2, and 5.
CENTRAL ILLUSTRATION Congenital Interventional Procedures and Outcomes
Procedure Attempted
Outcome Accomplished
Any AE
Major AE
Procedure Characteristics
ASD PDA PV PA (Stent)AV
AV
CoA
50
60
70
80
90
100
0
10
20
30
40
Common Congenital Interventions
IMPACT REGISTRY
ASD PDA PV PA (Stent)CoA
500
1000
1286
1375
270
305
671
245
% Balloon
Stent
Moore, J.W. et al. J Am Coll Cardiol. 2014; 64(23):2439–51.
The number of isolated common interventional procedure episodes reported to the IMPACT Registry between January 2011 and March 2013, as well as their outcomes.
AE ¼ adverse event; ASD ¼ atrial septal defect; AV ¼ aortic valvuloplasty; CoA ¼ coarctation of the aorta; PA ¼ pulmonary artery; PDA ¼ patent ductus arteriosus;
PV ¼ pulmonary valvuloplasty.
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2447DISCUSSION
As described here, in only 9 quarters during the Reg-
istry’s startup, IMPACT accumulated procedural
and safety data about large numbers of patients
undergoing 6 common congenital interventional pro-
cedures (Central Illustration). Percentage of proce-
dures completed and primary outcome accomplished(Figures 1 and 2), as well as AEs (Figure 3) were reported.
Numerous earlier single-center reports described only
relatively small numbers of patients with procedures
performed over fairly extended periods of time. Pre-
vious multicenter studies have been more substantial,
and some describe datasets comparable in size to
the IMPACT data reported here. This discussion brieﬂy
reviews these studies, including their procedural/
FIGURE 1 Procedures Completed
ASD
Closure
PDA
Closure
PV AV Coarct
Balloon/Stent
PA Stent
95.7
98.8
99.3
100
99.3 99.3
Procedure Completed
Percentages of intended procedures completed: atrial septal
defect (ASD) or patent ductus arteriosus (PDA) device or stent
implanted, valve, or vessel balloon dilation performed.
AV ¼ aortic valvuloplasty; Coarct ¼ coarctation of the aorta;
PA ¼ pulmonary artery; PV ¼ pulmonary valvuloplasty.
FIGURE 3 Adverse Events
ASD
Closure
PDA
Closure
PV AV Coarct
Balloon/Stent
PA Stent
1.21.2
13.217.3
24.3
3.3
7.15.3
0.2 01.2
5.7
Adverse Events
Any AE Major AE
Percentage of procedure episodes having adverse events (AEs);
other abbreviations as in Figure 1.
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2448technical elements and AE rates, juxtaposed with
IMPACT Registry data. Note that deﬁnitions of tech-
nical/procedural success and AEs used in the various
multicenter studies differ from those in this report.
DEVICE CLOSURE OF A SINGLE ASD. We described
procedural elements and safety data for 1,286
patients undergoing ASD device occlusion. Other
contemporary registries reported similar data for 478
patients (MAGIC, 12 centers) (10) having ASD closure
with the ASO and in 688 patients (C3PO, 8 centers)
having ASD closure with a mix of occluders (11). Other
substantial multicenter studies include the U.S. Food
and Drug Administration (FDA) sentinel studies of theFIGURE 2 Procedure Success
Primary Outcome Accomplished
ASD
Closure
PDA
Closure
PV AV Coarct
Balloon
Coarct
Stent
120
100
80
60
40
20
0
Percentage of completed procedures resulting in <3-mm
residual leak for ASD and PDA closures, <20 mm residual systolic
gradient for PV single balloon, <30 mm residual systolic gradient
for AV single balloon, and <10 mm residual gradient for Coarct
balloon and stent. Abbreviations as in Figure 1.ASO and the HELEX septal occluder. These were
prospective follow-up studies, which included
patient data to 1 year post-implantation. The ASO
study reported data for 442 patients at 29 centers (12),
and the HELEX study reported data for 119 patients at
14 centers (13). A successful ASD device implant rate
of 95.7% was reported to the IMPACT Registry, similar
to procedural success rates of 96% in the MAGIC
report, 95% in the C3PO report, and 95.7% (ASO) and
88.1% (HELEX) in the FDA studies. MAE and total AE
rates were 1.2% and 5.7%, respectively, in IMPACT
patients. These rates compare with 1.1% and 5.9%,
respectively, in MAGIC patients and with 4.7% and
11.5%%, respectively, in C3PO patients. AE rates in
the FDA studies include events occurring up to 1 year
post-implantation. These rates were 1.6% and 7.2%,
respectively, in ASO patients, and 5.9% and 33.6%,
respectively, in HELEX patients.
DEVICE CLOSURE OF PDA. With regard to PDA
occlusion, we described procedural elements and
safety data for 1,375 patients reported to the IMPACT
Registry. The Michigan PDA Coil Registry, an early
attempt to accumulate a large dataset describing use
of coils, was not published beyond abstract form. The
European PDA Registry retrospectively reported on
1,291 intended PDA coil occlusion procedures from
30 centers. Contemporary registries reported data
for 496 patients (C3PO, 8 centers) (14) and for
359 patients (MAGIC, 12 centers) (15). In addition, the
FDA study of the Amplatzer Duct Occluder (ADO)
was a multicenter prospective study that reported
efﬁcacy and safety results for 439 patients enrolled
at 25 centers (16). This study also included 1-year
post-implantation follow-up data. The FDA sentinel
study of the recently approved Nitocclud PDA
device included data for 357 patients enrolled at
15 centers, including 1-year follow-up data (17).
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2449Successful PDA occlusion device implantation in
98.8% was reported to IMPACT. In the European
Registry, procedure success was 94.3% in patients
having a PDA minimal diameter <6.2 mm. The MAGIC
and C3PO studies also used both devices and coils,
with reported procedure success rates of 99.4% and
96.8%, respectively. FDA sentinel studies for the ADO
and the Nitocclud PDA device reported on subsets of
larger or smaller PDAs. Procedure success rates in
the context of speciﬁc PDA size-related selection
criteria were 99% in the ADO study and 97.2% in the
Nitocclud study. AE rates reported to IMPACT were
0.2% (MAEs) and 5.3% (total AEs). In the European
Coil Registry, the rate of suboptimal outcomes
(failed procedures and AEs) was 10%. In the MAGIC
study, these rates were 2.3% and 4.6%, respectively,
and in the C3PO study, these rates were 2.0%
and 9.0%, respectively. The FDA studies reported
MAE rates of 2.3% and 0 and total AE rates of
7.1% and 4.7% in the ADO and Nitocclud studies,
respectively.
PULMONARY VALVULOPLASTY. This report de-
scribes 270 patients undergoing balloon valvuloplasty
for “typical” pulmonary valve stenosis. The C3PO
Registry recently reported similar data for 211 pa-
tients from 8 centers (18). Before the C3PO report, the
VACA Registry provided the only available (although
somewhat dated) multicenter data for 822 patients
treated in 26 centers (19). Among IMPACT patients,
balloon dilation of the valve was performed in all
but 2 patients (99.2%); however, only 73% achieved a
residual gradient <20 mm Hg. In the C3PO study,
all patients had valve dilation, and 91% achieved
procedure success, deﬁned primarily as gradient
reduction to #25 mm Hg. Similarly, all VACA study
patients had valve dilation, but only 91.9% achieved
gradient reduction to <30 mm Hg. There were no
MAEs reported in IMPACT patients; however, the
total AE rate was 7.1%. In C3PO patients, the MAE rate
was 3%, and the total AE rate was 12%. The VACA
report cited a MAE rate of 0.6% and a total AE rate
of 4.5%.
AORTIC VALVULOPLASTY. We described procedural
elements and safety information for 305 patients
having a single-balloon AV. There are no contem-
porary multi-institutional reports of balloon AV in
pediatric patients or in patients with congenital
aortic stenosis. VACA Registry, originally published
in 1990, reported data on 204 patients (20). In 1996,
an expanded VACA report analyzed 606 patients
from 23 participating institutions (21). Except for a
small Japanese study (22), the VACA reports provide
the only multicenter data available before IMPACTRegistry data. Aortic valve dilation was performed
in all IMPACT patients; however, only 61.5% of
procedures achieved a residual gradient <30 mm Hg.
Balloon dilation was not possible in 4.1% of VACA
patients. Of those in whom balloon dilation was
performed, 83% achieved a residual gradient <60
mm Hg or a residual left ventricular/aorta pressure
ratio <1.6. MAEs were reported in 3.3% and AEs were
reported in 24.3% of IMPACT patients. In VACA
patients, MAE and total AE rates were 5% and 17%,
respectively.
ANGIOPLASTY AND COARCT STENTING. We report
671 catheterization laboratory visits for balloon an-
gioplasty or Coarct stenting. Of 663 reported patients,
335 had angioplasty and 328 had either primary stent
implantation (n ¼ 251) or stent implantation after
balloon angioplasty (n ¼ 77). In 1996, the VACA in-
vestigators reported 970 procedures in 907 patients
treated with angioplasty in the 1980s and early 1990s
(23). A contemporary study, CCISC, reported on 350
patients enrolled from 36 institutions (24), comparing
patients having stent implantation (n ¼ 217) with
those having angioplasty (n ¼ 61) or surgery (n ¼ 72)
to treat Coarct. Balloon dilation and/or stent im-
plantation was performed in 99.0% of IMPACT
patients. Among patients having only balloon dila-
tion, 80.9% achieved a residual systolic gradient <20
mm Hg, whereas only 50.9% achieved a gradient <10
mm Hg. In patients having stent implantation, 83.7%
had residual gradients <10 mm Hg. In the VACA
study, all patients had angioplasty, but only 78%
achieved a residual gradient <20 mm Hg. In the CCISC
study, 56% of patients having only angioplasty and
76% of patients having stent implantation achieved
a residual gradient #10 mm Hg. In IMPACT, the
reported MAE rate was 1.2%, whereas the reported
total AE rate was 17.3%. In VACA patients, the MAE
rate was 2.7%, and the total AE rate was 14%. Among
CCISC patients, the reported total AE rate for both
stent and angioplasty patients was 4%, and no MAEs
were reported.
PA STENOSIS STENTING. We describe results from
245 catheterization laboratory visits for placement of
287 proximal PA stents. Historically, there were no
multicenter reports describing results of PA stenting
procedures. However, the C3PO Registry recently
reported data from 8 centers for balloon angioplasty
and stenting of branch PAs in 1,314 procedures, of
which 335 were proximal PA stents (25). Among
IMPACT patients, stent implantation in branch PAs
was reported in 99.3%; MAEs in 1.2%, and AEs in
13.2%. In C3PO, among patients having either angio-
plasty or stent implantation in proximal or more
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE:
Procedures directed at PDA and ASD closure are
among the safest and most successful procedures for
congenital heart disease in the United States
compared with aortic valvuloplasty and coarctation
angioplasty and/or stenting, which are generally less
successful and are associated with greater risk.
COMPETENCY IN PATIENT CARE: The IMPACT
database provides measures and predictors of proce-
dural success that may be considered in evaluating
patients with congenital heart disease for common
interventional procedures.
TRANSLATIONAL OUTLOOK: Longitudinal data
are needed to deﬁne the long-term effectiveness,
safety, and risk of mortality associated with
interventional procedures in patients with congenital
heart disease.
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2450distal branches, the MAE rate was 10% and the total
AE rate was 22%. C3PO did not specify these rates for
patients undergoing only stent implantation in
proximal branch PAs.
STUDY LIMITATIONS. Weaknesses and limitations of
this report reﬂect those of the IMPACT Registry itself.
Data are self-reported and, in this study, unaudited.
Self-reporting leads to possible reporting bias and
may result in missing data elements and incomplete
data for reported cases. The IMPACT/NCDR data
quality program prohibits analysis and reporting of
cases with inconsistent data and/or with signiﬁcant
missing data. However, cases with 1 or only a few
missing data elements may be considered adequate
for analysis and are included (9). Although NDCR Data
Quality Programs typically include an annual audit,
an auditing procedure for IMPACT is still under
development. Finally, aside from AEs recorded dur-
ing the entire episode of care, the Registry does not
collect longitudinal data.
CONCLUSIONS
This report provides the ﬁrst description from
the IMPACT Registry of procedural data and AEs
in patients undergoing 6 common congenital inter-
ventional procedures. This information is both
current and broadly representative of community
practice. Furthermore, the numbers of patients
described in the individual cohorts of this report
exceed or rival those reported in other registry and
multicenter studies. When IMPACT Registry proce-
dural success and AE rates are juxtaposed with
those of other studies, there are some similarities,
but also a number of discrepancies, which poseobvious opportunities for future analytic reports
from IMPACT.
The data reported here also provide some insights
into how commonly the interventions are performed
relative to each another and to the total catheteriza-
tion pool.
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